Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Schrödinger boxes up $110m
The drug development software provider has added $25m to an Alphabet and Wuxi AppTech-backed first tranche it closed in January.
Reneo generates $50m in series A round
Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.
Storm attracts more series A funding
M Ventures, Pfizer Ventures and Taiho Ventures all returned to help boost cancer drug developer Storm Therapeutics' series A round to $38.2m.
Zipline speeds up with $190m
Medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.
Solera seizes $42m in series C round
HCSC Ventures led the disease prevention platform's series C round, investing alongside Blue Cross Blue Shield Venture Partners.
Applied Therapeutics administers $40m IPO
Alexandria Real Estate Equities-backed Applied Therapeutics has gone public despite having to drastically cut its expectations for the offering.
DNA Script reaches series B chapter
Illumina Ventures and M Ventures made follow-on investments in synthetic DNA platform developer DNA Script as part of its $38.5m series B round.
Mahindra locates Centre of Sight for investment
Mahindra's private equity unit invested $29.3m in the ophthalmology centre operator, in a deal that enabled Matrix Partners India to exit.

Other News

Corporate venturing deal net: 13-17 May 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Icometrix processes $18m in funding
Optum Ventures co-led a round for Icometrix, the developer of a diagnostics system for neurological disorders, with Forestay Capital and Capricorn Venture Partners.
Phathom scares up $90m
Phathom Pharmaceuticals has been launched with $140m in debt and equity financing to commercialise a gastrointestinal disease drug licensed from Takeda.
Kevrekian seizes CVS Health promotion
Gregor Kevrekian, previously senior director of CVS Health’s corporate development and venture investing business, has ascended to executive director.
Healthineers prompts Siemens' Pompl to new role
René Pompl, formerly principal at Siemens’ Next47, has joined the corporate’s medical-focused Healthineers division as manager of venture technology.
Axcella accepts public listing
Metabolic therapy developer Axcella Health has priced its shares at $20 each in an offering that enabled Nestlé Health Science to exit.

Editor's Picks

Pfizer’s Jones to retire
Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.
M&A of the Year: Prexton Therapeutics
Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.
CVC in 2018 - The Trends: Part Two
In the second half of our guide to corporate venturing's biggest trends in 2018, we look at the growth of Chinese tech companies, genomics, advances in transport tech and the growth of the scooter rental space.
Relay Therapeutics runs away with $400m
SoftBank Vision Fund led a series B round for the cancer therapy developer that was also backed by GV and Alexandria Venture Investments.
test reg